Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
NCT04433988 · Sadat City University · PHASE1/PHASE2 · withdrawn · last registry update 2023-01-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Institutional problems” | – | Registry record, Sadat City University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADORA2B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-05Results posted on the registry: City of Hope Medical Center, 8-Chloroadenosine (NCT02509546)
- 2023-11-13Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., SHR-A1811 + Trastuzumab Emtansine (NCT06126640)
- 2023-11-02Phase 3 first posted: University of Utah, a drug against ADORA2B (NCT06112990)
- 2023-06-02Phase 3 first posted: University of Leicester, Low calorie meal replacement plan (NCT05887271)
- 2022-10-03Results posted on the registry: Processa Pharmaceuticals, PCS499 (NCT03698864)
- 2022-07-20Results posted on the registry: City of Hope Medical Center, trastuzumab + ado-trastuzumab emtansine (NCT02226276)
- 2022-07-12Results posted on the registry: Genzyme, a Sanofi Company, Alemtuzumab GZ402673 + Glatiramer acetate (NCT03368664)
- 2022-05-06Phase 3 first posted: Yale University, Green Tea Extract (NCT05364008)
- 2022-04-29Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan (T-DXd) + Ado-trastuzumab emtansine (T-DM1) (NCT03529110)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision